Metoprolol Succinate Tablet, Film Coated, Extended Release
Product Images NDC 82804-252

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Metoprolol Succinate (NDC 82804-252). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

82804-252-90 (Image 01)

82804-252-90 (Image 01)
This is a description for Metoprolol Succinate 25mg Extended-Release Tablets. The tablets are oval-shaped and film-coated, with a breakline on one side and 'A' and '3' debossed on each side of the breakline. They are white to off-white in color. Each tablet contains 23.75 mg of metoprolol succinate, equivalent to 25 mg of metoprolol tartrate. These tablets are manufactured by Alkem Laboratories Ltd. in India and packaged by Proficient Rx LP in Thousand Oaks, CA. The medication is prescription-only and should be kept out of the reach of children. The tablets are available in quantities of 30 and 90, with specific lot numbers and expiration dates provided on the packaging.*
FDA Label Image

Metoprolol-structure (Metoprolol Structure)

Metoprolol-structure (Metoprolol Structure)
FDA Label Image

Metoprolol-table1a (Metoprolol Table1a)

Metoprolol-table1a (Metoprolol Table1a)
This is a comparison of outcomes in the MERIT-HF study for different subgroups based on treatment with Metoprolol Succinate Extended-Release Tablets versus Placebo. The subgroups include patients from the United States and non-US countries, different New York Heart Association (NYHA) heart failure classes, various ejection fractions, ischemic and non-ischemic etiologies, male and female sexes, ethnicity, history of myocardial infarction, presence of diabetes mellitus, hypertension, and heart rate ranges. The analysis provides information on total mortality or hospitalization for heart failure, with relative risk and 95% confidence intervals given. It aims to evaluate how these factors may impact the effectiveness of Metoprolol Succinate in treating heart failure.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.